Abnova — Investor Presentation 2021

Nov 1, 2021

==> picture [129 x 42] intentionally omitted <==

亞諾法生技股份有限公司(4133.TW) 2021年法人說明會

創新的整合方案

2021/11/3

==> picture [751 x 70] intentionally omitted <==

==> picture [56 x 55] intentionally omitted <==

==> picture [77 x 153] intentionally omitted <==

免責聲明

本簡報及同時發佈之相關訊息包含財務、市場暨產品業務等預測性資訊。本 公司未來實際發生的營運結果及財務狀況可能與這些預測性資訊所明示或暗 示的預估有所差異，其原因可能來自於各種本公司所不能掌控的風險。這些 預估及展望的訊息，反應本公司截至目前為止對於未來的看法，本公司並不 負責隨時提醒或更新。

2

2

==> picture [77 x 153] intentionally omitted <==

今日議程

 亞諾法公司簡介 亞諾法公司介紹與沿革

==> picture [26 x 9] intentionally omitted <==

----- Start of picture text -----


----- End of picture text -----

2021年第二季與上半年財務成果 2021年第二季及上半年合併損益表與產品別營收分析

 亞諾法產品系列簡介 2021年最新產品開發進展

==> picture [112 x 33] intentionally omitted <==

3



亞諾法公司簡介

4

4

亞諾法公司介紹與沿革

==> picture [451 x 228] intentionally omitted <==

==> picture [331 x 188] intentionally omitted <==

==> picture [331 x 188] intentionally omitted <==

==> picture [451 x 227] intentionally omitted <==

5

5

==> picture [525 x 162] intentionally omitted <==

==> picture [193 x 171] intentionally omitted <==

==> picture [525 x 162] intentionally omitted <==

==> picture [194 x 146] intentionally omitted <==

==> picture [294 x 189] intentionally omitted <==

==> picture [427 x 189] intentionally omitted <==

6

6

==> picture [582 x 532] intentionally omitted <==

7

7

==> picture [595 x 348] intentionally omitted <==

==> picture [595 x 174] intentionally omitted <==

8

8



==> picture [32 x 46] intentionally omitted <==

2021年第二季與上半年財務成果

9

9

2021年第二季及上半年合併損益表

	Q2‘21	%	Q2‘20	%	H1‘21	%	H1‘20	%	H1 YOY
營業收入	124,254	100.00%	103,319	100%	238,582	100.00%	203,229	100.00%	17.40%
營業成本	‐70,557	‐56.78%	‐56,609	‐54.79%	‐133,377	‐55.90%	‐110,523	‐54.38%	20.68%
營業毛利	53,697	43.22%	46,710	45.21%	105,205	44.10%	92,706	45.62%	13.48%
營業費用	‐39,677	‐31.93%	‐38,309	‐37.08%	‐79,203	‐33.20%	‐77,020	‐37.90%	2.83%
營業利益	14,020	11.28%	8,401	8.13%	26,002	9.90%	15,686	7.72%	‐65.77%
營業外收入及支出	‐4,503	‐3.62%	‐3,009	‐2.91%	‐4,282	‐2.79%	‐900	‐0.44%	375.78%
稅前淨利	9,517	7.66%	5,392	5.22%	21,720	8.10%	14,786	7.28%	‐46.90%
稅後淨利	6,917	5.57%	4,122	3.99%	16,679	5.99%	11,818	5.82%	41.13%
基本每股盈餘	0.11		0.07		0.28		0.2

10

10

產品別營收分析

台幣(單位:千)

==> picture [303 x 301] intentionally omitted <==

----- Start of picture text -----

COVID-19
相關
25%
抗體
47%
其他
17%
蛋白質
11%
2021年 1~8月
----- End of picture text -----

11



亞諾法產品系列簡介

12

12

亞諾法產品系列簡介

COVID-19 印度變種中和性酵素免疫分析試劑組 COVID-19印度變種假病毒中和性抗體檢測試劑組

COVID-19 中和性抗體檢測快篩

COVID-19 SAM 通用型疫苗開發

攝護腺癌SAM 疫苗開發

CytoQuest™ CR

attIL-12 細胞治療開發

13

13

COVID-19 印度變種中和性酵素免疫分析 試劑組

COVID-19 Delta Variant Neutralizing Antibody ELISA Kit

==> picture [334 x 202] intentionally omitted <==

==> picture [309 x 219] intentionally omitted <==

14

14

COVID-19 印度變種假病毒中和性抗體 檢測試劑組

COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay

==> picture [710 x 215] intentionally omitted <==

15

COVID-19 印度變種假病毒中和性抗體 檢測試劑組

COVID-19 Delta Variant Pseudovirus Neutralizing Antibody Assay

==> picture [614 x 26] intentionally omitted <==

==> picture [613 x 73] intentionally omitted <==

==> picture [454 x 144] intentionally omitted <==

16

16

COVID-19 中和性抗體檢測快篩

監測疫苗接種後中和抗體效價

==> picture [405 x 113] intentionally omitted <==

==> picture [345 x 179] intentionally omitted <==

==> picture [418 x 113] intentionally omitted <==

==> picture [298 x 393] intentionally omitted <==

17

17

COVID-19 SAM 通用型疫苗開發

==> picture [708 x 137] intentionally omitted <==

==> picture [751 x 128] intentionally omitted <==

==> picture [751 x 129] intentionally omitted <==

18

18

COVID-19 SAM 通用型疫苗開發

==> picture [339 x 307] intentionally omitted <==

==> picture [426 x 154] intentionally omitted <==

==> picture [426 x 154] intentionally omitted <==

19

19

COVID-19 SAM 通用型疫苗開發

==> picture [531 x 121] intentionally omitted <==

==> picture [531 x 121] intentionally omitted <==

==> picture [529 x 209] intentionally omitted <==

20

20

COVID-19 SAM 通用型疫苗開發

==> picture [396 x 412] intentionally omitted <==

==> picture [398 x 264] intentionally omitted <==

21

21

COVID-19 SAM 通用型疫苗開發

==> picture [394 x 428] intentionally omitted <==

==> picture [397 x 250] intentionally omitted <==

22

22

COVID-19 SAM 通用型疫苗開發

==> picture [487 x 163] intentionally omitted <==

==> picture [487 x 24] intentionally omitted <==

==> picture [399 x 100] intentionally omitted <==

==> picture [399 x 181] intentionally omitted <==

==> picture [338 x 16] intentionally omitted <==

==> picture [370 x 216] intentionally omitted <==

23

COVID-19 SAM 通用型疫苗開發

==> picture [478 x 20] intentionally omitted <==

==> picture [375 x 169] intentionally omitted <==

==> picture [375 x 170] intentionally omitted <==

==> picture [372 x 168] intentionally omitted <==

==> picture [372 x 168] intentionally omitted <==

==> picture [568 x 47] intentionally omitted <==

==> picture [601 x 36] intentionally omitted <==

24

24

攝護腺癌SAM 疫苗開發

in vitro models

in vivo models

==> picture [519 x 124] intentionally omitted <==

25

CytoQuest™ CR

中國第三類醫療器械認證許可

==> picture [492 x 308] intentionally omitted <==

==> picture [268 x 218] intentionally omitted <==

==> picture [185 x 167] intentionally omitted <==

==> picture [561 x 77] intentionally omitted <==

==> picture [112 x 33] intentionally omitted <==

26

attIL-12細胞治療開發

膀胱癌人源腫瘤異種移植小鼠模型

==> picture [773 x 228] intentionally omitted <==

==> picture [773 x 115] intentionally omitted <==

27

27

==> picture [131 x 189] intentionally omitted <==

Thank You

Abnova Innovate through Integrated Solutions

==> picture [751 x 70] intentionally omitted <==

==> picture [56 x 55] intentionally omitted <==